摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-Hydroxy-2-thien-2-yl-thieno<3,2-d>pyrimidin | 18678-18-7

中文名称
——
中文别名
——
英文名称
4-Hydroxy-2-thien-2-yl-thieno<3,2-d>pyrimidin
英文别名
2-thiophen-2-yl-3H-thieno[3,2-d]pyrimidin-4-one;2-thiophen-2-yl-3H-thieno[3,2-d]pyrimidin-4-one
4-Hydroxy-2-thien-2-yl-thieno<3,2-d>pyrimidin化学式
CAS
18678-18-7
化学式
C10H6N2OS2
mdl
MFCD18131591
分子量
234.302
InChiKey
GFESGQDULHILFG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    15
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    97.9
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    4-Hydroxy-2-thien-2-yl-thieno<3,2-d>pyrimidin三氯氧磷 作用下, 生成 C10H5ClN2S2
    参考文献:
    名称:
    Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives
    摘要:
    We describe herein the discovery and development of a series of 4-arylthieno[3,2-d]pyrimidines which are potent adenosine A(2A) receptor antagonists. These novel compounds show high degrees of selectivity against the human A(1), A(2B) and A(3) receptor sub-types. Moreover, a number of these compounds show promising activity in vivo, suggesting potential utility in the treatment of Parkinson's disease. (C) 2008 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2008.03.076
  • 作为产物:
    描述:
    3-(thiophene-2-carbonylamino)thiophene-2-carboxamide 在 sodium hydroxide 作用下, 生成 4-Hydroxy-2-thien-2-yl-thieno<3,2-d>pyrimidin
    参考文献:
    名称:
    Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives
    摘要:
    We describe herein the discovery and development of a series of 4-arylthieno[3,2-d]pyrimidines which are potent adenosine A(2A) receptor antagonists. These novel compounds show high degrees of selectivity against the human A(1), A(2B) and A(3) receptor sub-types. Moreover, a number of these compounds show promising activity in vivo, suggesting potential utility in the treatment of Parkinson's disease. (C) 2008 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2008.03.076
点击查看最新优质反应信息

文献信息

  • WO2008/92862
    申请人:——
    公开号:——
    公开(公告)日:——
  • Ried,W.; Giesse,R., Justus Liebigs Annalen der Chemie, 1968, vol. 713, p. 143 - 148
    作者:Ried,W.、Giesse,R.
    DOI:——
    日期:——
  • [EN] BICYCLIC DERIVATIVES AS EP4 AGONISTS<br/>[FR] DÉRIVÉS BICYCLIQUES UTILISÉS COMME AGONISTES DE EP4
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2008092862A1
    公开(公告)日:2008-08-07
    [EN] The present invention relates to a compound of formula (I) including any stereochemical isomeric form thereof, wherein A represents a 5 or 6-membered aromatic optionally substituted heterocycle containing 1, 2 or 3 heteroatoms; ring E represents a partially saturated or aromatic 5-membered heterocycle wherein the dotted lines represent an optional double bond and wherein B, C and D each independently represent CH2, CH, N, NH, S or O and F represents N or C, provided that the 5-membered ring contains 1, 2 or 3 heteroatoms; X represents a direct bond or C1-4alkanediyl; Y represents N or CH; R1 represents hydrogen or fluoro; R2 represents hydrogen, halo, cyano, C1-6alkyl, C1-6alkyloxy, C1-6alkylcarbonyl or C1-6alkylcarbonylamino; R3 represents hydrogen, halo, C1-6alkyl, C1-6alkyloxy, cyano, nitro, amino or mono-or di(C1-6alkyl)amino; n represents an integer of value 1, 2 or 3; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The claimed compounds are useful for the treatment of a disease by activating the EP4 receptor.
    [FR] L'invention concerne un composé représenté par la formule (I) comprenant une forme isomère stéréo chimique quelconque de ce composé, un N-oxyde de celui-ci, un sel pharmaceutiquement acceptable de celui-ci ou un solvate de celui-ci. Dans cette formule, A représente un composé hétérocyclique aromatique éventuellement substitué à 5 ou 6 éléments contenant 1, 2 ou 3 hétéroatomes; un noyau E représente un composé hétérocyclique à 5 éléments aromatique ou partiellement saturé, les lignes en pointillé représentant une liaison double facultative, B, C et D représentant chacun indépendamment CH2, CH, N, NH, S ou O, et F représentant N ou C, à condition que le noyau à 5 éléments contienne 1, 2 ou 3 hétéroatomes; X représente représente une liaison directe ou C1-4alkanédiyle; Y représente N ou CH; R1 représente hydrogène ou fluoro; R2 représente hydrogène, halo, cyano, C1-6alkyle, C1-6alkyloxy, C1-6alkylcarbonyle ou C1-6alkylcarbonylamino; R3 représente hydrogène, halo, C1-6alkyle, C1-6alkyloxy, cyano, nitro, amino ou mono- ou di(C1-6alkyl)amino; n représente un nombre entier de valeur 1, 2 ou 3. Les composés précités sont utilisés pour traiter une maladie par activation du récepteur EP4.
  • Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives
    作者:Roger J. Gillespie、Ian A. Cliffe、Claire E. Dawson、Colin T. Dourish、Suneel Gaur、Paul R. Giles、Allan M. Jordan、Antony R. Knight、Anthony Lawrence、Joanne Lerpiniere、Anil Misra、Robert M. Pratt、Richard S. Todd、Rebecca Upton、Scott M. Weiss、Douglas S. Williamson
    DOI:10.1016/j.bmcl.2008.03.076
    日期:2008.5
    We describe herein the discovery and development of a series of 4-arylthieno[3,2-d]pyrimidines which are potent adenosine A(2A) receptor antagonists. These novel compounds show high degrees of selectivity against the human A(1), A(2B) and A(3) receptor sub-types. Moreover, a number of these compounds show promising activity in vivo, suggesting potential utility in the treatment of Parkinson's disease. (C) 2008 Elsevier Ltd. All rights reserved.
查看更多

同类化合物

林扎戈利 替普司特 噻吩并[3,4-d]嘧啶-2,4(1H,3H,5H,7H)-二酮 噻吩并[3,2-d]嘧啶-7-甲胺 噻吩并[3,2-d]嘧啶-4-羧酸 噻吩并[3,2-d]嘧啶-4(1H)-硫酮 噻吩并[3,2-d]嘧啶,4-(甲硫基)- 噻吩并[3,2-d]嘧啶 噻吩并[3,2-D]嘧啶-7-羧酸 噻吩并[3,2-D]嘧啶-7-甲醛 噻吩并[3,2-D]嘧啶-7-基甲醇 噻吩并[3,2-D]嘧啶-2-胺 噻吩并[2,3-d]嘧啶-4-胺 噻吩并[2,3-d]嘧啶-4-硫醇 噻吩并[2,3-d]嘧啶-4(3H)-酮 噻吩并[2,3-d]嘧啶-2,4-二胺 噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮,3-(3-甲氧苯基)-6-(4-甲氧苯基)-5-甲基- 噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮,3-(3-氯苯基)-1-[(2,6-二氟苯基)甲基]-6-(4-甲氧苯基)-5-甲基- 噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮,3-(2-氯苯基)-1-[(2,6-二氟苯基)甲基]-6-(4-甲氧苯基)-5-甲基- 噻吩并[2,3-d]嘧啶 噻吩并[2,3-D]嘧啶-6-羧酸 噻吩并[2,3-D]嘧啶-6-甲醛 吡啶并[3’,2’:4,5]噻吩并[3,2-d]嘧啶-4(3h)-酮 乙基3-甲基-5-羰基-5H-[1]苯并噻吩并[2,3-d][1,3]噻唑并[3,2-a]嘧啶-2-羧酸酯 乙基2-(4-氯苯基)-7-甲基-9-羰基-9H-[1,3]噻唑并[3,2-a]噻吩并[3,2-d]嘧啶-6-羧酸酯 {[((4-氧代-3,4,5,6,7,8-六氢[1]苯并噻吩并[2,3-d]嘧啶-2-基)甲基]硫基}乙酸 [(6-甲基噻吩并[2,3-d]嘧啶-4-基)硫基]乙酸 [(4-氧代-3,4,5,6,7,8-六氢[1]苯并噻吩并[2,3-d]嘧啶-2-基)硫基]乙酸 PI3K抑制剂 PF-3758309抑制剂 Necrostatin-5; 2-[[3,4,5,6,7,8-六氢-3-(4-甲氧基苯基)-4-氧代[1]苯并噻吩并[2,3-d]嘧啶-2-基]硫代]-乙腈 N-甲基-1-噻吩并[3,2-d]嘧啶-4-基-4-哌啶甲胺 N-[2-[[3,4-二氢-4-氧代-3-[4-(2,2,2-三氟乙氧基)苯基]噻吩并[3,4-d]嘧啶-2-基]硫基]乙基]乙酰胺 N-[(1S)-2-(二甲基氨基)-1-苯基乙基]-2,6-二氢-6,6-二甲基-3-[(2-甲基噻吩并[3,2-d]嘧啶-4-基)氨基]-吡咯并[3,4-c]吡唑-5(4H)-甲酰胺盐酸盐 N-(6-甲基-2-苯并噻唑基)-2-[(3,4,6,7-四氢-3-(2-甲氧基苯基)-4-氧噻吩并[3,2-d]嘧啶-2-基)硫代]-乙酰胺 N-(4-氟苯基)-5,6-二甲基噻吩并[2,3-D]嘧啶-4-胺 N-(4-吗啉-4-基噻吩并[2,3-e]嘧啶-2-基)乙烷-1,2-二胺 N,N-二甲基-5,6,7,8-四氢苯并[4,5]噻吩并[2,3-D]嘧啶-4-胺 IWP2;N-(6-甲基-2-苯并噻唑基)-2-[(3,4,6,7-四氢-4-氧代-3-苯基噻吩并[3,2d]嘧啶-2-基)硫基]乙酰胺 AR-C 155858; (S)-6-[(3,5-二甲基-1H-吡唑-4-基)甲基]-5-[(4-羟基异噁唑烷-2-基)羰基]-1-异丁基-3-甲基噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮 7-甲基噻吩并[3,2-D]嘧啶-4-胺 7-甲基-噻吩并[3,2-d]嘧啶-2,4(1h,3h)-二酮 7-甲基-噻吩并[3,2-d]嘧啶 7-甲基-5,6,7,8-四氢[1]苯并噻吩并[2,3-d]嘧啶-4(3h)-酮 7-甲基-5,6,7,8-四氢-苯并[4,5]噻吩并[2,3-d]嘧啶-4-硫醇 7-溴噻吩并[3,2-d]嘧啶 7-溴噻吩并[3,2-D]嘧啶-4(1H)-酮 7-溴-噻吩并[3,2-d]嘧啶-4-胺 7-溴-4-氯噻酚并[3,2-D]嘧啶 7-溴-2-氯噻吩并[3,2-D]嘧啶